Concepedia

Serban Ghiorghiu

SG

Statistics

Publications

20

Citations

10.8K

H-Index

16

Active since

2004

Affiliations

AstraZeneca (United Kingdom)(Current)

Seoul National University Hospital

Emory University

Dana-Farber Cancer Institute

National Taiwan University Hospital

Serban Ghiorghiu is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and egfr inhibition.

ORCID

Publications per year

2004–2023

20

Publications

20

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

, , +16

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

, , +13

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

, , +16

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd et al. · The Lancet Oncology · 2016 · 643 citations

, , +9

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2017 · 572 citations · Full text

, , +15

1–5 of 20